 Invo Bioscience Inc NASDAQ: INVO shares have gained sharply after an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain geographical restrictions. 